Post Transplant Lymphoproliferative Disorder, Other Malignancies, And Serious Infections

• Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system.
• Recipients wthout immunity to Epstein-Barr virus (EBV) are at a particularly increased risk; therefore, use in EBV seropositive patients only.
• Do not use this drug in transplant recipients who are EBV seronegative or with unknow EBV serostatus [See Contraindications and Warnings and Precautions]
• Increased suseptibility to infection and the possible development of malignancies may result rom immunosuppression. [See Warnings and Precautions]

• Only physicians experienced in immunosuppressive therapy and management of kidney transplant patients should prescribe belatacept. The physician responsible fpr maintenance therapy should have complete information requisite for the follow-up of the patient.
• Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and suportive medical resources.

• Use in liver transplant patients is not recommended due to increased risk of graft loss and death. [See Warnings and Precautions]